(NASDAQ: NPCE) Neuropace's forecast annual revenue growth rate of 8.91% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 7.11%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.61%.
Neuropace's revenue in 2025 is $94,864,000.On average, 10 Wall Street analysts forecast NPCE's revenue for 2025 to be $3,321,946,850, with the lowest NPCE revenue forecast at $3,166,233,194, and the highest NPCE revenue forecast at $3,428,365,061. On average, 10 Wall Street analysts forecast NPCE's revenue for 2026 to be $3,364,414,211, with the lowest NPCE revenue forecast at $3,158,072,799, and the highest NPCE revenue forecast at $3,602,231,432.
In 2027, NPCE is forecast to generate $4,250,733,013 in revenue, with the lowest revenue forecast at $3,913,658,745 and the highest revenue forecast at $4,530,517,979.